Acadia Pharmaceuticals

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Acadia Pharmaceuticals 是一家在股票代码 ACAD (US) 下上市的公司。

查看带有其 42 名主要高管的组织结构图

Acadia Pharmaceuticals 搜索最多的简介

• Catherine Owen, Chief Executive Officer and Director
• Laura Brege, Director
• Edmund Harrigan, Director

高管在Acadia Pharmaceuticals变化

• Thomas Garner已作为Chief Commercial Officer加入公司  (新闻发布的2024十二月10号).
• Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial, 将于 202412月31 退休  (新闻发布的2024十一月22号).
• Catherine Owen已作为Chief Executive Officer and Director加入公司  (新闻发布的2024九月24号).

更多的变化在％s

创建提醒
跟踪 Acadia Pharmaceuticals 的高管变动

Acadia Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Stemtech and Seacret Direct have announced they will merge  (公布2024十二月5号)..
• Recursion Pharma and Exscientia have merged  (公布2024十一月27号)..
• Stemtech and Seacret Direct have announced they will merge  (公布2024十一月22号)..

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

Acadia Pharmaceuticals 的最新新闻稿

• Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - Acadia Pharmaceuticals
• Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - Acadia Pharmaceuticals
• Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome - Acadia Pharmaceuticals
• View more press releases Close

关于 Acadia Pharmaceuticals 的社交媒体

• Acadia Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Acadia Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Edmund Harrigan

致电Acadia Pharmaceuticals，电话：+1 858...

查看组织结构图

Register to receive your alert

报告错误